[ad_1]
Fintel reports that on April 21, 2023, Morgan Stanley reiterated coverage of Disc Medicine (NASDAQ:IRON) with a Overweight recommendation.
Analyst Price Forecast Suggests 17.13% Upside
As of April 6, 2023, the average one-year price target for Disc Medicine is $36.72. The forecasts range from a low of $32.32 to a high of $42.00. The average price target represents an increase of 17.13% from its latest reported closing price of $31.35.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -$0.27.
What is the Fund Sentiment?
There are 53 funds or institutions reporting positions in Disc Medicine. This is an increase of 40 owner(s) or 307.69% in the last quarter. Average portfolio weight of all funds dedicated to IRON is 0.62%, an increase of 12,600,557.13%. Total shares owned by institutions increased in the last three months by 16,180.49% to 11,140K shares. The put/call ratio of IRON is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
Atlas Venture Life Science Advisors holds 3,462K shares representing 18.22% ownership of the company.
Novo Holdings A holds 2,341K shares representing 12.32% ownership of the company.
Orbimed Advisors holds 2,161K shares representing 11.37% ownership of the company.
5AM Venture Management holds 588K shares representing 3.10% ownership of the company.
Janus Henderson Group holds 500K shares representing 2.63% ownership of the company.
See all Disc Medicine regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link
